- Report
- June 2024
- 200 Pages
Global
From €7255EUR$7,950USD£6,186GBP
- Clinical Trials
- June 2024
- 1761 Pages
Global
From €3149EUR$3,450USD£2,685GBP
- Report
- November 2024
- 150 Pages
Global
From €4426EUR$4,850USD£3,774GBP
- Report
- May 2024
- 133 Pages
Global
From €5931EUR$6,499USD£5,057GBP
- Report
- January 2022
- 60 Pages
Global
From €3605EUR$3,950USD£3,074GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1825EUR$2,000USD£1,556GBP
- Report
- March 2024
- 200 Pages
Global
From €3787EUR$4,150USD£3,229GBP
- Report
- May 2023
- 57 Pages
Global
From €3646EUR$3,995USD£3,109GBP
- Drug Pipelines
- August 2020
- 345 Pages
Global
From €1825EUR$2,000USD£1,556GBP
- Drug Pipelines
- July 2023
- 144 Pages
Global
From €13685EUR$14,995USD£11,669GBP
- Report
- October 2024
- 102 Pages
Global
From €3500EUR$4,108USD£3,089GBP
- Report
- April 2022
- 330 Pages
Global
From €2282EUR$2,500USD£1,945GBP
The Dyslipidemia Drug market is a subset of the Cardiovascular Drugs market, which focuses on the treatment of dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. Dyslipidemia drugs are used to reduce the risk of cardiovascular disease, stroke, and other cardiovascular complications. These drugs are typically administered orally and can be divided into two categories: statins and non-statin drugs. Statins are the most commonly prescribed drugs for dyslipidemia, as they are effective in reducing cholesterol levels. Non-statin drugs, such as fibrates, bile acid sequestrants, and cholesterol absorption inhibitors, are also used to treat dyslipidemia.
The Dyslipidemia Drug market is highly competitive, with many large pharmaceutical companies offering a variety of drugs. Some of the major players in the market include Pfizer, Merck, Sanofi, AstraZeneca, Novartis, and Bristol-Myers Squibb. Show Less Read more
